MELISSA COLAROSSI: Open Payments
NPI 1528610334 · HONESDALE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,254 in 58 payments from 13 companies in 2025. Trend: 2023 $1,338 · 2024 $187 · 2025 $1,254
Food & beverage: $1,254
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $343 |
| Novo Nordisk Inc | 16 | $247 |
| Lilly USA, LLC | 8 | $193 |
| Eisai Inc. | 4 | $90 |
| Tandem Diabetes Care, Inc. | 3 | $74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $70 |
| SCPHARMACEUTICALS INC. | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
| Dexcom, Inc. | 2 | $43 |
| Amgen Inc. | 2 | $36 |
Products named: UBRELVY, QULIPTA, ZEPBOUND, JARDIANCE, Wegovy, Leqembi, Ozempic, t:slim X2 Insulin Pump with Control-IQ.
Industry payments across PA — which companies pay providers there.
